Lasker Awards Honor Breakthroughs in Sleep Science, Hemophilia, and Parkinson's Advocacy

America's Nobel Prizes Shine a Light on Decades of Dedication

On Wednesday, September 9, the Lasker Foundation announced its 2026 award winners, recognizing landmark advances in narcolepsy research, hemophilia treatment, and Parkinson's disease advocacy. Often called "America's Nobel," the Lasker Awards come with a $250,000 prize per category and carry enormous prestige — more than 80 past recipients have gone on to win the Nobel Prize since the foundation was established in 1945.

This year's honorees represent the full arc of medical progress: from the laboratory bench, to the clinic, to the public stage. Together, they reflect how scientific discovery, therapeutic innovation, and determined advocacy can each play a critical role in improving — and saving — lives.

Cracking the Mystery of Narcolepsy

The basic medical research award went to Emmanuel Mignot of Stanford University and Masashi Yanagisawa of the University of Tsukuba in Japan. Working independently, the two scientists made a discovery that fundamentally changed how medicine understands narcolepsy: the condition, in many cases, is caused by the absence of a brain chemical called orexin. It sounds simple in retrospect, but it took years of painstaking neuroscience to get there.

Narcolepsy affects an estimated one in 2,000 people in the United States — a relatively rare condition, but one that can be profoundly disabling, causing sudden sleep attacks, muscle weakness, and an inability to maintain a normal waking life. The work by Mignot and Yanagisawa didn't just explain why; it opened a door. Their discovery has since translated into an FDA-approved drug that targets the orexin system, giving patients a treatment grounded in the actual biology of their disease rather than trial-and-error symptom management.

A New Era for Hemophilia A Patients

The clinical medical research award recognized a trio of scientists — Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa — for developing a drug to treat hemophilia A, a bleeding disorder in which the blood cannot clot properly. For generations, hemophilia A patients faced a grueling treatment regimen involving frequent infusions of clotting factor, often with serious complications. The drug developed by this team represents a meaningful shift in how the condition can be managed, offering patients a more targeted and potentially more accessible therapeutic option.

The recognition underscores how clinical research — the painstaking work of moving a scientific idea from concept to patient bedside — deserves the same level of honor as fundamental discovery. Getting a drug right, and getting it to the people who need it, is its own kind of breakthrough.

Michael J. Fox and the Power of a Famous Voice

Perhaps the most emotionally resonant award went to actor Michael J. Fox, who received the public service award for his decades of work raising awareness and funding for Parkinson's disease research. Diagnosed with Parkinson's in 1991 at just 29 years old, Fox founded the Michael J. Fox Foundation, which has become one of the largest private funders of Parkinson's research in the world.

His recognition by the Lasker Foundation affirms something the scientific community has increasingly come to understand: public advocacy is not a soft complement to hard science — it is a force multiplier. Fox's willingness to speak openly about his diagnosis helped destigmatize the disease, drove hundreds of millions of dollars toward research, and kept Parkinson's in the national conversation for more than three decades. As research into neurological diseases accelerates, the foundation he built will likely play a role in whatever breakthroughs come next.